The cost of genome sequencing has decreased substantially over the past two decades. In 2001, sequencing a human genome – the complete set of genetic information in a human being – cost approximately USD 100 million. Through technological advances such as parallelization of sequencing, throughput increases, and lower cost chemistry, costs have come down to approximately USD 562, according to the latest data from August 2021. The big promise for low-cost genome sequencing is the ability to analyze millions of samples which could improve diagnostics and therapeutics. Instead of looking at a tiny part of the genome (due to high costs) we can now look at the whole genome, resulting in a better understanding of biology.
It is said that a picture paints a thousand words. Robeco’s Trends Investing team monitors markets closely. Every morning our trends experts collect the most relevant and intriguing graph or chart for you and present it with their commentary in the Daily Sketch. All graphics provided are collected from Bloomberg data or other public websites. They do not necessarily reflect the opinion of Robeco. Please cite all references or quote the original source if replicating content.
More about Trends Investing.
Robeco Institutional Asset Management B.V. (DIFC Branch) is regulated by the Dubai Financial Services Authority (“DFSA”) and only deals with Professional Clients and Market Counterparties, and does not deal with Retail Clients as defined by the DFSA.
Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.